13 July 2018 - - Minneapolis, Minnesota-based developer of scientific testing materials and controls Bio-Techne Corp. (NASDAQ: TECH) has been validating an extensive and growing number of antibodies using recent advances in gene editing technology, the company said.
The CRISPR gene editing system is now being utilised by Bio-Techne for the validation of antibodies in knockout (KO) cell lines.
This methodology is one of the proposed, and currently most effective, negative controls identified by the International Working Group for Antibody Validation.
Bio-Techne has now validated R and D Systems- and Novus Biologicals-branded antibodies for over 110 different targets from a range of CRISPR KO-modified cell lines and partnered with two gene-editing companies, B-MoGen Biotechnologies and EdiGENE Corp., to produce biologically relevant data for nearly 1,000 antibody products.
The KO antibody initiative covers a range of targets from receptors, enzymes, transcription factors, and autophagy markers to immune checkpoint molecules. Bio-Techne gene knockouts are produced in over 10 different cell line models.
Additionally, Bio-Techne performs antibody validation for various applications using KO cell lines, including Western blot, immunocytochemistry, and flow cytometry.
Bio-Techne develops and manufactures cytokines and growth factors, antibodies, and immunoassays, as well as biologically active small molecule compounds and ACD's in situ hybridization detection products which are sold to biomedical researchers and clinical research laboratories.
The company's products are used in scientific investigations into biological processes and disease, aiding in drug discovery efforts and providing the means for accurate clinical tests and diagnoses.